COPD

IvelinRadkov Sanofi (NASDAQ:SNY) and its partner Regeneron (NASDAQ:REGN) announced Wednesday that the EU drug regulator, the European Medicines Agency (EMA), has approved a label expansion for their asthma therapy Dupixent to include patients with the lung disorder, chronic obstructive pulmonary disease (COPD). The approval marks the first time a globalContinue Reading